✦ LIBER ✦

Evaluation of CA-125 response in the TRINOVA-1 study of weekly paclitaxel plus trebananib or placebo in women with recurrent ovarian cancer

✍ Scribed by Herzog, T.J.; Richardson, G.E.; Monk, B.J.; Karlan, B.Y.; Marth, C.; Navale, L.; Warner, D.J.; Oza, A.M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Health-related quality-of-life analysis

✍ Raspagliesi, F.; Lhommé, C.; Monk, B.J.; Coleman, R.L.; Herzog, T.J.; Navale, L. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Phase 1–2 study of docetaxel plus aflibe

✍ Robert L Coleman; Linda R Duska; Pedro T Ramirez; John V Heymach; Aparna A Kamat 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 208 KB

Phase 1/2 study of weekly paclitaxel wit

✍ G. Falchook; B. Goff; R. Kurzrock; H. Gray; L. Martin; R. Coleman; H. Xiao; X. Z 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 132 KB